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Assessment of the biodistribution of an [18F]
FDG-loaded perfluorocarbon double emulsion
using dynamic micro-PET in rats
Mario L. Fabiilli*, Morand R. Piert, Robert A. Koeppe, Phillip S. Sherman,
Carole A. Quesada and Oliver D. Kripfgans
Perﬂuorocarbon (PFC) double emulsions loaded with a water-soluble, therapeutic agent can be triggered by
ultrasound in a process known as acoustic droplet vaporization. Elucidating the stability and biodistribution of these
sonosensitive vehicles and encapsulated agents is critical in developing targeted drug delivery strategies using
ultrasound. [18F]ﬂuorodeoxyglucose (FDG) was encapsulated in a PFC double emulsion and the in vitro diffusion
of FDG was assessed using a Franz diffusion cell. Using dynamic micro-positron emission tomography and direct
tissue sampling, the biodistribution of FDG administered as a solution (i.e. non-emulsiﬁed) or as an emulsion was
studied in Fisher 344 rats (n=6) bearing subcutaneous 9L gliosarcoma. Standardized uptake values (SUVs) and area
under the curve of the SUV (AUCSUV) of FDG were calculated for various tissues. The FDG ﬂux from the emulsion
decreased by up to a factor of 6.9 compared with the FDG solution. FDG uptake, calculated from the AUCSUV,
decreased by 36% and 44% for brain and tumor, respectively, when comparing FDG solution vs FDG emulsion (p
0.01). Decreases in AUCSUV in highly metabolic tissues such as brain and tumor demonstrated retention of FDG
within the double emulsion. No statistically signiﬁcant differences in lung AUCSUV were observed, suggesting mini-
mal accumulation of the emulsion in the pulmonary capillary bed. The liver AUCSUV increased by 356% for the FDG
emulsion, thus indicating signiﬁcant hepatic retention of the emulsion. Copyright © 2013 John Wiley & Sons, Ltd.
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1. INTRODUCTION
Nano- or micron-sized perﬂuorocarbon (PFC) particles are com-
monly used in diagnostic and therapeutic applications of
ultrasound. For example, surfactant-stabilized, PFC microbubbles
(i.e. contrast agents) are clinically utilized for perfusion imaging
(1,2) and can be speciﬁcally targeted to vascular receptors,
such as vascular endothelial growth factor receptor (3,4). Micro-
bubbles can also facilitate drug or gene delivery, in response to
ultrasound, when a therapeutic agent is either co-administered
with the contrast agent (5,6) or the agent is contained/bound
within the contrast agent (7,8). Gas-ﬁlled contrast agents have
also been used to enhance the effects of thermal ablation
achieved by high-intensity focused ultrasound (HIFU) (9). As
highlighted in a recent review (10), various types of liquid PFC
droplets have also been investigated as diagnostic imaging
agents. Similarly, PFC emulsions have been used therapeutically
for ultrasound-triggered drug delivery (11–14) and HIFU (15,16).
Understanding the pharmacokinetics of sonosensitive PFC parti-
cles and the biodistribution of therapeutic agents contained within
the particles is critical in developing ultrasound-based, drug
delivery therapies that are safe and efﬁcacious. For example,
lung retention of microbubbles within the pulmonary microvas-
culature is a size-dependent phenomenon (17). The formulation
of transpulmonary, micron-sized emulsions can minimize certain
types of PFC-related bioeffects (18,19). Additionally, the pharma-
cokinetics of sonosensitive PFC particles are directly related
to the time window between vascular administration of the
particles and the application of ultrasound to activate the parti-
cles. For nanoparticles that are passively targeted to tumor
tissue, sufﬁcient extravasation must occur to achieve an optimal
therapeutic outcome (16,20).
Various imaging modalities – such as positron emission
tomography (PET) (21–24), magnetic resonance (MR) (20,25) and
ﬂuorescence (20,26–28) imaging – have been used to study the
in vitro cellular localization and in vivo biodistribution of both PFC
microbubbles (21–24,28) and droplets (20,25–27). Depending
on the type of PFC particle (i.e. diagnostic vs therapeutic) and
incorporated imaging marker (e.g. 19F for MRI or 18F for PET),
these modalities enable the visualization of the PFC phase,
surfactant or therapeutic payload. Small animal PET (i.e. micro-
PET) enables the study of pre-clinical biodistribution in a serial
or paired manner and does not require the sacriﬁce of animals
for direct tissue sampling. PET is an attractive imaging technique
given its high sensitivity and clinical translatability, when compared
with optical imaging techniques. Additionally, PET enables treat-
ment monitoring and planning (29), thereby potentially leading
to more individualized medical care (30).
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In the presented studies, micro-PET is used to determine the
biodistribution of a water-soluble radiotracer contained within
a micron-sized, sonosensitive double emulsion of the following
structure: water-in-PFC-in-water (W1/PFC/W2); similar double
emulsion formulations have been used both in vitro (31,32) and
ex vivo (33). Water-soluble agents, contained within the W1
phase, can be released using ultrasound in a process known
as acoustic droplet vaporization (ADV) (34,35). Upon exposure
to ultrasound above a certain acoustic pressure amplitude, the
PFC liquid within the sonosensitive emulsion is converted into
a gas. Thus, this double emulsion belongs to a class of PFC
emulsions that have been termed phase-shift (16,36) or phase-
change (37) emulsions. Low boiling point PFCs – such as
perﬂuorobutane (C4F10, 2C), perﬂuoropentane (C5F12, 29C) or
perﬂuorohexane (C6F14, 56C) – are typically used in emulsions that
undergo ADV in order to minimize the acoustic pressures that are
required for vaporization at normal body temperature (37C) (38).
In addition to drug delivery (11–14,20,26,31,32,39,40), ADV has
been utilized in medical applications such as embolotherapy
(41–43), enhancement of HIFU (15,16) and phase aberration
correction (41,44). The primary excretion route of vascularly-
administered PFC emulsions is via the mononuclear phagocyte
system (MPS), where the particles accumulate primarily in the
liver and spleen (45,46); the PFC is then transported to the lung
for exhalation (47).
Elucidating the biodistribution of sonosensitive emulsions,
in the absence of ADV, is critical in the development of safe
and effective ADV-based therapies. To our knowledge, this is
the ﬁrst study that uses PET to track the biodistribution of a
radiolabeled compound encapsulated within a sonosensitive,
PFC double emulsion. [18F]ﬂuorodeoxyglucose (FDG) – a water-
soluble, radiotracer used in glucose utilization studies for
tumor, cardiac and cerebral tissue – was incorporated into the
W1 phase of the double emulsion. First, the stability of the
FDG-loaded emulsion was studied in vitro. Second, the biodistri-
bution of emulsiﬁed FDG was evaluated in rats using both
dynamic micro-PET and traditional tissue sampling techniques.
The biodistribution of the FDG emulsion and non-emulsiﬁed
(i.e. free) FDG was studied sequentially in rats to assess the
in vivo stability of the emulsion, with a focus on the retention
of FDG within the emulsion.
2. RESULTS
2.1. Characterization And In Vitro Stability Of Emulsion
The size distributions of the FDG emulsion, obtained using
a Coulter counter, are displayed in Fig. 1. The mean droplet
diameter is 1.5 0.1 mm and the droplet number density is
2.6 0.5 1010 droplets/ml. The vast majority of the droplet
volume (93%) is contained within droplets whose diameters
are 6 mm or less. There were no statistically signiﬁcant changes
in the size distributions of the emulsion after 24 h, thereby
indicating in vitro stability of the emulsion in the presence of
high energy b+ (positron) and g radiation (FDG).
2.2. In Vitro Release Of FDG
The retention of FDG within the emulsion, as evaluated using a
Franz diffusion cell, is shown in Fig. 2. All values in Fig. 2 were
corrected for the aliquots of solution and hence FDG activity
removed during sampling. A solution of FDG, equal in activity
to the emulsion, was used as a control. It was conﬁrmed, by
mixing blank (i.e. without FDG) emulsion and FDG solution, that
the presence of the droplets within the donor compartment did
not statistically change the FDG diffusion across the membrane
for the FDG solution.
The ﬂux of FDG was calculated based on a linear regression
of the data between 10 and 60 min, which yielded squared
correlation coefﬁcients greater than 0.99 in all cases. In saline,
the ﬂuxes for the FDG solution and emulsion were 0.14 0.003
and 0.02 0.007 MBq/cm2/min, respectively. In plasma, the
ﬂuxes for the FDG solution and emulsion were 0.13 0.004
and 0.03 0.01 MBq/cm2/min, respectively. Therefore, in saline
and plasma, the ﬂux of FDG is reduced, respectively, by a factor
of 6.9 and 4.2, compared with the solution, when FDG is
encapsulated in the double emulsion.
2.3. In Vivo Dynamic Micro-PET Of Emulsion
Representative micro-PET images, scaled based on the standard-
ized uptake value (SUV), are shown in Fig. 3. Qualitatively, it can
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Figure 1. Number and volume-weighted distributions of the perﬂuoro-
carbon (PFC) double emulsion containing [18F]ﬂuorodeoxyglucose (FDG)
as obtained by the Coulter counter.
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Figure 2. Normalized activity of FDG in the acceptor compartment of
the Franz diffusion cell for the FDG solution and FDG emulsion. In both
cases, an equal concentration of FDG was loaded into the donor compart-
ment. The average activity (n=3) and standard deviation is plotted for
each data point.
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be observed that the uptake of FDG is higher for the FDG solu-
tion (Fig. 3, left) than the FDG emulsion (Fig. 3, right) for the
denoted organs and tumor, except the liver. Figure 4 displays
the time proﬁles of the SUV for brain, lung, liver, tumor, muscle
and blood for both FDG solution and FDG emulsion. Statistically
signiﬁcant decreases of 36% and 44% were observed for the area
under the curve for the normalized time activity data (AUCSUV)
when comparing FDG emulsion vs FDG solution for brain and
tumor, respectively. The liver displayed a 356% increase in
the AUCSUV when comparing FDG emulsion vs FDG solution.
No statistically signiﬁcant changes in AUCSUV were noted for lung,
muscle or blood. Additionally, activity levels in blood obtained
from the left ventricular cavity were probably overestimated for
both FDG emulsion and solution, due to the ‘spill-in’ of activity
from the myocardium. Statistically signiﬁcant differences in the
maximum area under the curve (AUCMAX) were observed with
brain and liver; a 36% decrease and 120% increase in AUCMAX
occurred in brain and liver, respectively. No statistically
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Figure 3. Coronal micro-PET images of a rat that received an injection of FDG solution (left) and FDG emulsion (right). The summed images (0–60 min)
are SUV-scaled (scale bar on far right).
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Figure 4. Time–activity curves of intravenously injected FDG solution and FDG emulsion, measured by dynamic micro-PET, in Fisher 344 rats with 9L
tumors (n=6). The data represent mean and standard deviation of the SUV for the (a) brain, (b) lung, (c) liver, (d) tumor, (e) muscle and (f) blood.
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signiﬁcant differences in the time to reach AUCMAX (tMAX) or the
time required for the SUV to reach half of AUCMAX (t1/2) were ob-
served except in liver, which displayed increases of 321% and
498%, respectively. The control rats that received FDG solution
on day 1 followed by blank (i.e. without FDG) emulsion and
FDG solution on day 2 did not display any statistically signiﬁcant
differences in AUCSUV, AUCMAX, tMAX or t1/2 for the time proﬁles
measured on days 1 and 2.
2.4. Direct Tissue Sampling Studies
The biodistribution of FDG measured as percentage injected
dose per gram tissue (%ID/g) in various organs and tissues at 3
min post-injection is shown in Fig. 5. Uptake of FDG solution
and emulsion is also shown in Table 1. For all organs and
tissues, except heart and adrenal glands, a statistically signiﬁcant
difference in uptake was observed when comparing FDG solu-
tion vs FDG emulsion. Except for lung, liver and spleen, the
uptake was lower for the FDG emulsion than for the FDG
solution. When comparing the activity for the FDG solution and
FDG emulsion, decreases of 62%, 59% and 57% were observed
for brain, tumor and muscle, respectively. For lung, liver and
spleen, the uptake (in %i.d./g) increased by 384%, 122% and
609% when comparing FDG emulsion vs FDG solution.
3. DISCUSSION
Focused ultrasound has been used to localize drug release from
vascularly administered sonosensitive emulsions (13,20,40,48).
The timing between the administration of the emulsion and
the subsequent application of ultrasound to generate ADV
and localized release is critical in achieving efﬁcacious results.
A sufﬁcient delay following the injection of the emulsion can
facilitate therapy via intended mechanisms of particle accumula-
tion, such as binding of actively targeted droplets to vascular
receptors (25,49) or the extravasation of nano-sized emulsions
in a tumor (20). However, the efﬁcacy of localized drug delivery
from sonosensitive emulsions can be negatively affected by
unintended release (i.e. release in the absence of ultrasound
sufﬁcient to trigger ADV) or clearance of the emulsion via
the MPS. Additionally, as observed with other emulsions (50), the
formulation of a therapeutic agent as an emulsion can dramat-
ically change the biodistribution and pharmacokinetics of
the agent.
One main aim of this study was to demonstrate stable
retention of the payload (i.e. FDG) within the W1 phase such
that release of the payload could be triggered by ultrasound
via ADV. By minimizing the amount of burst release from the
emulsion upon injection, the spatial and temporal proﬁles of
drug release can be localized by the application of focused
ultrasound. This precise control of drug release is especially
useful when delivering agents that are systemically toxic (e.g.
chemotherapeutic agents), such that drug release and uptake
are localized to the intended target site (e.g. tumor).
As demonstrated in Fig. 2, the ﬂux of FDG is reduced when
encapsulated in the double emulsion. This decrease in diffusion
rate, which is consistent with previous studies using ﬂuorescein
within the W1 phase (31), is attributed to the hydrophobic
perﬂuoro-n-pentane (PFP) layer that surrounds the W1 phase
(47). Given that the ﬂux of FDG from the emulsion is non-zero,
there are four potential mechanisms by which FDG could be
diffusing from the emulsion: (1) spontaneous vaporization of
PFP within the emulsion, thereby releasing the W1 phase; (2)
conversion of the double emulsion into a single emulsion
(i.e. PFC/W2); (3) diffusion of FDG from the W1 phase into the bulk
phase in the absence of PFP vaporization or emulsion destabiliza-
tion; or (4) diffusion of residual FDG, probably present in the
W2 phase, that remains post-washing. Although ﬂuorocarbon
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Figure 5. Biodistribution of FDG solution (n=6) and FDG emulsion
(n= 6) in Fisher 344 rats with 9L tumors at 3 min. The data represent
mean and standard deviation of each organ/tissue. In all cases except
for heart and adrenal glands, a statistically signiﬁcant difference (p
0.01) was observed when comparing solution vs emulsion.
Table 1. FDG uptake in various organs and tissues obtained 3 min post-intravenous injection. The average uptake (n= 6) and
standard deviation are listed for each data point
Uptake (%ID/g)
FDG Brain Lung Liver Tumor Muscle
Solution 1.42 0.19 1.39 0.11 2.03 0.18 1.67 0.45 0.16 0.04
Emulsion 0.54 0.09 6.72 1.66 4.52 0.76 0.68 0.13 0.07 0.01
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emulsions have been used as radiation dosimetry detectors
(51,52), whereby the emulsion transitions from liquid droplets
into gas bubbles when exposed to radiation, the double emulsion
used in this work is stable in the presence of high-energy
radiation resulting from the decay of ﬂuorine-18. This is probably
due to the boiling point of PFP (29C), which is signiﬁcantly
higher than the boiling point of ﬂuorocarbons typically used in
dosimetry applications (i.e. <0C). Therefore, spontaneous
vaporization is probably not causing release of FDG from the
emulsion. Additionally, since the volume fraction of W1 in the
double emulsion is large (31), the conversion of the double emul-
sion into a single emulsion – an instability issue with double
emulsions (53) – should be detectable by measuring the droplet
size distribution. Again, no differences in size distribution were
observed when comparing the initial droplet size distribution to
that one day later; therefore, this mechanism seems unlikely, at
least in vitro. It is hypothesized that FDG release from the emul-
sion is due to FDG diffusing from the W1 phase, without emulsion
destabilization and/or the presence of residual FDG in the W2
phase that was not removed during washing.
The comparative in vivo uptake of FDG, whether in free form
(i.e. solution) or emulsiﬁed, is an indicator of the degree to which
FDG is stably retained within the emulsion. This retention can be
clearly seen by comparing the time–activity curves for brain and
tumor (Fig. 4a and d) – two tissues that display high levels of glu-
cose utilization and retention of FDG. In both cases, statistically
signiﬁcant decreases in the AUCSUV, an indicator of the exposure
and uptake of the radiotracer (54), were observed (Fig. 4), thus
conﬁrming that emulsiﬁcation hinders uptake of FDG. For both
FDG solution and FDG emulsion, the AUCSUV was higher in tumor
than brain, which is probably due to the anesthetic isoﬂurane that
decreases FDG uptake in rodent brain (55), but not in tumor tissue
(56), vs the awake state. The decrease in FDG uptake due to emul-
siﬁcation is further supported by Fig. 6, which displays relative
SUVs between scans of data shown in Fig. 4. These relative SUVs
are calculated as the SUV of the ‘FDG emulsion’ scan divided by
the SUV of the ‘FDG solution’ scan at each time point. Similarly,
for the control rats, relative SUVs are given by the SUV of the
‘FDG solution+blank emulsion’ scan divided by the ‘FDG solution’
scan. For the control animals, the relative SUVs are close to 1,
which indicates that the presence of blank emulsion did not affect
FDG metabolism. It is important to note that any afﬁnity that FDG
has for the emulsion (e.g. binding to the the Poloxamer shell),
which may be evident with the FDG emulsion, would not neces-
sarily be present in this control given that the rats were injected
with FDG solution followed by blank emulsion.
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Figure 6. Relative SUVs are calculated as the SUV of the ‘FDG emulsion’ scan divided by the SUV of the ‘FDG solution’ scan (Figure 4). For control
rats, relative SUVs are given by the SUV of the ‘FDG solution+blank emulsion’ scan divided by the ‘FDG solution’ scan. The data represent mean
and standard deviation for the (a) brain, (b) lung, (c) liver, (d) tumor, (e) muscle and (f) blood.
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For rats that received FDG emulsion, the relative SUVs are
generally <1. The fraction of FDG retained within the emulsion
vs the total FDG can be estimated using the data in Fig. 6. When
the blood–brain barrier (BBB) extraction is high and the tissue
blood fraction is low, the fraction of FDG in the emulsion is
simply 1 minus the values shown in Fig. 6. However, as extrac-
tion decreases or blood volume increases, a simple correction
factor is needed. Assuming that the brain blood volume frac-
tion is 3%, the BBB extraction fraction is 0.2, and a relative
SUV of 0.5, the fraction of FDG retained in the emulsion at 5
min is ~58%. The fraction of FDG retained in the emulsion is
fairly consistent for brain and tumor. It can also be observed
in Fig. 6 that the relative SUVs in brain, tumor and muscle
increase slowly from 5 min through the end of the scan. This
probably indicates that a smaller fraction of FDG becomes
available for transport out of the blood due to FDG release from
the droplets. Thus, by the end of the study, the fraction of FDG
retained in the emulsion has decreased to around 40–45%.
Comparatively, if all of the FDG were to be retained in the
emulsion, the relative SUV would be 0.13.
Minimizing PFC accumulation in the lung is critical in prevent-
ing the disruption of pulmonary gas exchange (18,19), which can
cause respiratory distress or death (43,57). One approach to
minimize lung effects generated by PFC emulsions, as well as
ensuring uniform ADV thresholds of the emulsions, is to gener-
ate monodisperse droplets (37). As supported by the AUCSUV
(Fig. 4), no lung retention of the polydisperse FDG emulsion
was detected by micro-PET. Since 98% (by number) of the
droplets are 3 mm in diameter or smaller (Fig. 1), minimal lung
accumulation was expected given that a previous study demon-
strated clearance of 2mm and 3mm rigid microparticles in rat
lungs (58). Based on direct tissue sampling (Fig. 5), there was a
statistically signiﬁcant increase in lung activity at 3 min for the
FDG emulsion compared with the FDG solution. However, the
AUCSUV for lung between 0 – 3 min indicates no statistically sig-
niﬁcant differences. The relative SUV (Fig. 6b) between 0.75 and
6.5 min displays mean values >1, although the differences are
not statistically signiﬁcant relative to the control rats. Thus, it is
hypothesized that the differences in observed lung uptake
between the micro-PET and tissue sampling studies may be
due to differences in the duration of isoﬂurane exposure, a
vasodilator (59). Isoﬂurane was administered for 15–20 min and
5 min prior to the administration of the emulsion in the micro-
PET and biodistribution tissue sampling studies, respectively.
Previous studies have demonstrated that PFC emulsions
accumulate in organs of the MPS such as liver and spleen
(45,46). Signiﬁcant accumulation of the FDG emulsion was
conﬁrmed by both micro-PET imaging (Figs 4c and 6c) and direct
tissue sampling (Fig. 5) in both the liver and spleen. The largest
increases in AUCSUV, AUCMAX, tMAX, t1/2 and uptake were
observed in liver and spleen when comparing FDG emulsion vs
FDG solution – another indicator that FDG is being retained
within the double emulsion. Due to the faster rate of clearance
(i.e. ~ 150% higher) of FDG from the liver for the FDG emulsion
compared with the FDG solution, as determined by the slope
of the time-activity curves in Fig. 4(c) between 12.5 – 55 min,
it may be likely that FDG is released from the emulsion while
accumulated in the liver. Incorporating polyethylene glycol
(PEG) chains or PEG-containing polymers into the shell stabiliz-
ing the double emulsion could reduce the rate at which the
droplets are opsonized (i.e. the rate at which droplets are
marked for phagocytic clearance) and removed by the MPS
(60,61). Although Poloxamer 188, the water-soluble surfactant
used to stabilize the double emulsion, is a copolymer containing
PEG, it has not been found to reduce hepatic or splenic uptake of
particles (62,63).
4. CONCLUSIONS
As demonstrated both in vitro and in vivo, small, water-soluble
molecules such as FDG can be retained in sonosensitive double
emulsions. Given that drug release from PFC emulsions can be
triggered using ultrasound, the retention of the encapsulated
payload in the W1 phase is critical in spatially and temporally
localizing release to the site of ultrasound application. Dynamic
micro-PET imaging indicated that the FDG emulsion did not
accumulate in the lung, which is critical in minimizing PFC
related bioeffects. When delivering a therapeutic agent in the
PFC double emulsion, the use of surfactants such as Poloxamer
407 or Poloxamine 908 could assist in decreasing the rate
at which the droplets are cleared by the MPS and thereby
modulating the release of drug into the general circulation.
Given the observed distribution of the FDG loaded into the
sonosensitive emulsion, the liver will probably be a critical organ
when therapeutic payloads are used.
5. EXPERIMENTAL
5.1. Emulsion Preparation
The double emulsion was prepared by modifying previously
published methods (31). The primary emulsion (W1/PFC) was
formed by dissolving Krytox 157 FSL (CAS no. 51798-33-5,
DuPont, Wilmington, DE, USA), a perﬂuoroether with carboxylic
acid functionality, and Krytox 157 FSL-polyethylene glycol
copolymer in perﬂuoro-n-pentane (CAS no. 678-26-2, Strem
Chemicals, Inc., Newburyport, MA, USA) at concentrations of 25
and 75 mg/ml, respectively. The PFP phase was then combined
with an aqueous solution of FDG at a volumetric ratio of 4:3.
FDG was synthesized in-house by the Cyclotron and Radiochem-
istry Facility at the University of Michigan. The mixture was
emulsiﬁed, while in an ice bath, via sonication using a microtip
(model 450, 20 kHz, Branson, Danbury, CT, USA) operating at
125 W/cm2 for 30 s in continuous mode. The resulting primary
emulsion was added drop-wise to a 100 mg/ml solution of
Poloxamer 188 (Sigma Aldrich, St Louis, MO, USA) in normal
saline (0.9% w/v, Hospira Inc., Lake Forest, IL, USA), which
was in an ice bath and being stirred at 1100 rpm for 10 min.
Poloxamer 188 is a water-soluble, amphiphilic copolymer that
stabilizes the PFC/W2 interface, thus enabling the formation
of a double emulsion. The coarse double emulsion was then
sonicated, as previously described, to reduce droplet size. To
minimize the amount of non-emulsiﬁed FDG, the double emul-
sion was washed in triplicate by centrifuging the emulsion at
5000 rpm for 30 s, removing the supernatant, and resuspending
the pellet (i.e. droplets) in fresh saline. The double emulsion
was sized using a Coulter counter (Multisizer III, Beckman Coulter
Inc., Brea, CA, USA) with a 50 mm aperture and used immediately
for in vivo experiments. To assess the stability of the emulsion
in the presence of FDG, the remaining emulsion was stored
at room temperature (25C) and sized, as described previously,
24 h after formulation.
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5.2. In Vitro FDG Release
Release of FDG from the double emulsion was measured at room
temperature (25C) using a Franz diffusion cell (PermeGear,
Inc., Hellertown, PA, USA), as described previously (31). Brieﬂy,
a cellulose membrane (6–8 kDa molecular weight cutoff,
Spectrum Laboratories Inc., Rancho Dominguez, CA, USA), soaked
in normal saline was mounted between the donor and acceptor
compartments of the cell. The donor media contained 2 ml FDG
emulsion, diluted in either normal saline or human plasma, while
the acceptor compartment contained 7.5 ml of either normal
saline or human plasma (i.e. the same ﬂuid loaded in the donor
compartment). Near-sink conditions were maintained in the
acceptor compartment, which was stirred at 600 rpm, throughout
the duration of the experiment. The diffusion area between both
compartments was 1.77 cm2. Additionally, an overhead stirrer,
operating at 600 rpm, prevented settling of the emulsion on
the membrane owing to the elevated density of PFP (1.6 g/ml).
At 10 min intervals, aliquots of the acceptor medium were
withdrawn and immediately replaced with fresh, normal saline
or human plasma. The FDG activity was measured with a dose
calibrator (CRC 712M, Capintec Inc., Ramsey, NJ, USA). The above
experiment was repeated for an FDG solution of equal activity
as well.
5.3. Cell Line And Tumor Model
9L gliosarcoma cells (American Type Culture Collection, Manassas,
VA, USA) were cultured in Dulbecco’s modiﬁed Eagle medium
(high glucose) supplemented with 9% (v/v) fetal bovine serum,
100 U/ml penicillin, 0.1 mg/ml streptomycin, and 0.35 mg/ml
G418 (Geneticin). Cell culture media and reagents were obtained
from Gibco (Invitrogen, Eugene, OR, USA). The cells were grown
in a humidiﬁed 5% carbon dioxide environment at 37C. After
reaching 80% conﬂuence, 5 106 cells were trypsinized, resus-
pended in phosphate buffered saline, and injected subcutaneously
into the right shoulder of female Fischer 344 rats (n=12, 200 g;
Harlan Laboratories, Indianapolis, IN, USA). Tumors were allowed
to grow for 7–10 days. All animal protocols were approved by
the University Committee on Use and Care of Animals.
5.4. Dynamic Micro-PET Imaging
Rats (n=9) were anesthetized using isoﬂurane (5% for induction
and 1–2% for maintenance) and placed prone within a micro-PET
scanner (R4 or P4, Concorde Microsystems Inc., Knoxville, TN,
USA) (64). Body temperature, maintained using a circulating
water warming pad, and respiratory rate were monitored during
the imaging session. FDG solution (n=9, 7.4 MBq) was injected
via tail vein catheter immediately followed by a 60 min dynamic
PET scan with respiratory gating. The rats were allowed to
recover. On the following day, the aforementioned imaging
procedure was repeated for the FDG emulsion (n= 6, 1.9 MBq,
mass dose of emulsion 0.08 g PFP per kilogram body weight).
A control study was conducted to conﬁrm that the presence
of the emulsion alone did not alter the in vivo biodistribution
of FDG. Rather than receiving an injection of FDG emulsion,
the control rats (n=3) were injected with FDG solution (7.4 MBq)
immediately followed by blank (i.e. without FDG) emulsion
(mass dose of emulsion 0.08 g PFP per kilogram body weight).
All rats were recovered for tissue sampling (biodistribution)
studies on the following day.
5.5. Analysis Of Micro-PET Images
After correction for decay, dead time and random coincidences,
PET data were reconstructed using a statistical reconstruction
method (ordered-subset expectation maximization). Images
were scaled to the SUV, deﬁned as the measured radioactivity
(in nCi/cm3) normalized by the injected activity and body weight
of each rat. Time–activity curves were generated for individual
volumes of interest drawn in various organs and tissues using
the ASI Pro VM software (Siemens Medical Systems, Malvern,
PA, USA). The time–activity curve for blood was generated by
analyzing the left ventricular cavity.
MATLAB (The MathWorks Inc., Natick, MA, USA) was used
to calculate the following parameters: AUCSUV, AUCMAX, tMAX
and t1/2.
5.6. Direct Tissue Sampling (Biodistribution) Studies
The FDG solution (n=6, 1.9 MBq) or FDG emulsion (n=6, 1.9 MBq,
mass dose of emulsion 0.08 g PFP per kilogram body weight) was
administered intravenously in anesthetized rats. Three minutes
after injection, the following tissues were harvested: brain, eyes,
heart, lung, liver, pancreas, spleen, adrenal glands, kidneys,
adipose tissue, ovaries, uterus, muscle (thigh), bone (femur),
blood and tumor. Radioactivity was counted in a g-counter
(model A5550, Minaxi auto gamma, Packard/Perkin Elmer,
Waltham, MA, USA). Decay-corrected results were expressed as
percentage of injected radioactivity dose per gram of tissue (%ID/g).
5.7. Statistical Analysis
Each experimental value is expressed as the mean standard
deviation and the result of at least three independent measure-
ments. Statistically signiﬁcant differences between experimental
groups was determined using a Student’s t-test. A signiﬁcance
level of 0.01 was used for all comparisons.
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